ArticleBMC infectious diseases2026
Hospital length of stay and cost associated with routine-care documentation of probable or suspected fungal infection among patients hospitalized with acute myeloid leukemia: a propensity score analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungal infection remains a recurring concern during inpatient care for acute myeloid leukemia (AML), but many hospitals lack local estimates of the bed-day and cost burden associated with fungal-infection documentation. We estimated excess length of stay (LOS) and hospitalization cost associated with routine-care documented probable or suspected fungal infection (PFI) among AML inpatient encounters.
methodsWe conducted a retrospective encounter-level study using routinely collected 2020-2025 AML inpatient data from the electronic medical record database of Ganzhou People's Hospital. PFI was identified from prespecified fungal-infection terms in diagnosis text and microbiology fields (excluding records with an explicitly negative fungal result) to define routine-care documented PFI. Outcomes were LOS and total hospitalization cost in Chinese yuan (Renminbi; RMB, also CNY). The primary estimand was the average treatment effect among the treated (ATT). We fitted crude, propensity score matching, inverse probability of treatment weighting (IPTW), and doubly robust models. Sensitivity analyses evaluated alternative weighting and matching choices, robust uncertainty, PFI documentation source, patient-level clustering, cost missingness, and the feasibility of an early-PFI definition.
resultsThe analytic cohort comprised 2,686 AML inpatient encounters; 661 (24.6%) were classified as PFI and 2,025 as non-PFI. Median LOS was 18.97 days in the PFI group and 7.06 days in the non-PFI group. Among encounters with observed cost, median hospitalization cost was 24,888.24 RMB in the PFI group and 7,681.44 RMB in the non-PFI group. In the primary IPTW-ATT analysis, PFI was associated with 10.17 excess hospital days (95% CI, 8.49 to 11.85) and 20,542.01 RMB excess hospitalization cost (95% CI, 16,361.90 to 24,722.11). Doubly robust ATT estimates were similar: 10.21 days for LOS and 20,613.70 RMB for cost. Heteroskedasticity-robust (non-clustered) standard errors yielded directionally consistent intervals for IPTW-ATT: LOS 10.17 days (95% CI, 8.81 to 11.53) and cost 20,542 RMB (95% CI, 17,205 to 23,879). Cost was missing in 506 encounters (18.8%); cost-missing encounters differed modestly from cost-observed encounters.
conclusionsIn this single-hospital AML inpatient dataset, documented PFI was associated with a higher-burden hospital course, including longer LOS and higher observed cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.